Abstract
In recent years, an increasingly detailed picture of gastrointestinal dysfunction
in the setting of Parkinson’s disease has emerged. Abnormalities of function may occur
at virtually all levels of the gastrointestinal tract. Weight loss, dental deterioration,
salivary excess, dysphagia, gastroparesis, decreased bowel movement frequency, and
anorectal dysfunction all may occur. The pathophysiologic basis for this dysfunction
entails both central and enteric nervous system involvement.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Parkinsonism & Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- An essay on the shaking palsy.Whittingham and Rowland, London1817
- Diet, body size and micronutrient status in Parkinson’s disease.Eur J Clin Nutr. 1992; 46: 879-884
- Weight change and body composition in patients with Parkinson’s disease.J Am Diet Assoc. 1995; 95: 979-983
- Parkinson’s disease and weight loss: a study with anthropometric and nutritional assessment.Clin Auton Res. 1992; 2: 153-157
- Gastrointestinal dysfunction in Parkinson’s disease.Lancet Neurol. 2003; 2: 107-116
- Weight and body mass index in Parkinson’s disease patients after deep brain stimulation surgery.Parkinsonism Relat Disord. 2005; 11: 247-252
- Compulsive eating and weight gain related to dopamine agonist use.Mov Disord. 2006; 21: 524-529
- Oral health conditions in patients with Parkinson’s disease.J Epidemiol. 2004; 14: 143-150
- Increased periodontal pathology in Parkinson’s disease.J Neurol. 2006; 253: 608-611
- Influence of Parkinson’s disease on oral health.Acta Odontol Scand. 1992; 50: 37-42
- Oral health of patients with Parkinson’s disease: factors related to their better dental status.Tohoku J Exp Med. 2003; 201: 171-179
- Bruxism as a presenting feature of Parkinson’s disease.J Assoc Physicians India. 2002; 50: 457
- An appliance for management of TMJ pain as a complication of Parkinson’s disease.Cranio. 1998; 16: 57-59
- Habitual mandibular dislocation in two patients with Parkinson’s disease.Rinsho Shinkeigaku. 1999; 39 ([Japanese]): 849-851
- Burning mouth in Parkinson’s disease sufferers.Gerodontology. 1998; 15: 73-78
- Sialorrhoea and drooling in patients with Parkinson’s disease: epidemiology and management.Drugs Aging. 2008; 25: 1007-1019
- Impact of drooling in Parkinson’s disease.J Neurol. 2007; 254: 1227-1232
- Sialorrhea in Parkinson’s disease: a review.Mov Disord. 2007; 22: 2306-2313
- Alimentary disorder in parkinsonism.Aust Ann Med. 1965; 14: 13-22
- Gastrointestinal symptoms in Parkinson’s disease.Mov Disord. 1991; 6: 151-156
- Salivary symptoms in Parkinson disease.Arch Neurol. 1973; 29: 274-275
- A study of salivary secretion in Parkinson’s disease.Clin Neuropharmacol. 1999; 22: 213-215
- Salivary production in Parkinson’s disease.Mov Disord. 2005; 20: 204-207
- Quantitative study of salivary secretion in Parkinson’s disease.Mov Disord. 2006; 21: 660-667
- Is drooling secondary to a swallowing disorder in patients with Parkinson’s disease?.Parkinsonism Relat Disord. 2008; 14: 243-245
- Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study.Mov Disord. 2002; 17: 1318-1320
- Ipratropium bromide spray as treatment for sialorrhea in Parkinson’s disease.Mov Disord. 2007; 22: 2268-2273
- Botulinum toxin: clinical use.Parkinsonism Relat Disord. 2006; 12: 331-355
- Long-term follow-up of tympanic neurectomy for sialorrhea.Laryngoscope. 1979; 89: 1219-1223
- Referral criteria for speech and language therapy assessment of dysphagia caused by idiopathic Parkinson’s disease.Acta Neurol Scand. 1998; 97: 27-35
- Prepharyngeal dysphagia in Parkinson’s disease.Dysphagia. 1996; 11: 14-22
- Swallowing abnormalities and their response to treatment in Parkinson’s disease.Neurology. 1989; 39: 1309-1314
- Pharyngo-esophageal dysphagia in Parkinson’s disease.Dysphagia. 1997; 12: 11-18
- Swallowing difficulty in Parkinson’s disease.Clin Neurol Neurosurg. 1997; 99: 106-112
- Swallowing disorders in Parkinson’s disease.Parkinsonism Relat Disord. 2003; 9: 349-353
- Asymptomatic swallowing disorders in elderly patients with Parkinson’s disease: a description of findings on clinical examination and videofluoroscopy in sixteen patients.Age Aging. 1994; 23: 251-254
- Dysphagia, a reversible cause not to be forgotten.Postgrad Med J. 1995; 71: 94-95
- Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders.Arch Neurol. 2001; 58: 259-264
- Mechanisms of oral-pharyngeal dysphagia in patients with Parkinson’s disease.Gastroenterology. 1996; 110: 383-392
- Videofluorographic study of swallowing in Parkinson’s disease.Dysphagia. 1998; 13: 95-100
- Swallowing and speech production in Parkinson’s disease.Ann Neurol. 1986; 19: 283-287
- Radiological assessment of dysphagia in Parkinson’s disease.Br J Radiol. 1991; 64: 890-893
- Cricopharyngeal dysfunction in Parkinson’s disease: role in dysphagia and response to myotomy.Mov Disord. 1996; 11: 53-58
- Gastrointestinal dysfunction in Parkinson’s disease. A report of clinical experience at a single center.J Clin Gastroenterol. 1994; 19: 11-16
- Biomechanics of failed deglutitive upper esophageal sphincter relaxation in neurogenic dysphagia.Am J Physiol Gastrointest Liver Physiol. 2002; 283: G16-G26
- Esophageal manometric abnormalities in Parkinson’s disease.Dysphagia. 1998; 13: 28-31
- Manometric abnormalities of the oesophagus in patients with Parkinson’s disease.Neurogastroenterol Motil. 2001; 13: 361-364
- Esophageal disorders and surgery.in: Biller J. The interface of neurology & internal medicine. Lippincott Williams & Wilkins, Philadelphia2008: 217-221
- Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson’s disease.Mov Disord. 1996; 11: 729-732
- Botulinum toxin for cricopharyngeal dysfunction in Parkinson’s disease.N Engl J Med. 2002; 346: 1174-1175
- Gastrointestinal dysfunction in Parkinson’s disease.Semin Neurol. 1996; 16: 245-250
- Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient.Neurology. 1981; 31: 1288-1294
- Gastric emptying in Parkinson’s disease: patients with and without response fluctuations.Neurology. 1996; 46: 1051-1054
- Gastric emptying time and gastric motility in patients with Parkinson’s disease.Mov Disord. 2001; 16: 1041-1047
- Predictors of gastric emptying in Parkinson’s disease.Neurogastroenterol Motil. 2006; 18: 369-375
- Gastric emptying after semi-solid food in multiple system atrophy and Parkinson disease.J Neurol. 2005; 252: 1055-1059
- Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson’s disease.Isr J Med Sci. 1996; 32: 1224-1227
- Erratic gastric emptying of levodopa may cause “random” fluctuations of Parkinsonian mobility.Neurology. 1988; 38: 419-421
- Current management of motor fluctuations in patients with advanced Parkinson’s disease treated chronically with levodopa.J Neural Transm Suppl. 1999; 56: 173-183
- Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson’s disease with a fluctuating response to levodopa.Eur J Clin Pharmacol. 1991; 41: 453-458
- Irregular gastrointestinal drug absorption in Parkinson’s disease.Expert Opin Drug Metab Toxicol. 2008; 4: 193-203
- Gastroparesis: current diagnostic challenges and management considerations.World J Gastroenterol. 2009; 15: 25-37
- Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine.Am J Gastroenterol. 2008; 103: 753-763
- Impaired gastric emptying of a solid test meal in patients with Parkinson’s disease using 13C-sodium octanoate breath test.Neurosci Lett. 2005; 375: 170-173
- Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.Clin Neuropharmacol. 2006; 29: 61-67
- Domperidone and levodopa in Parkinson’s disease.Br J Clin Pharmac. 1984; 18: 959-962
- Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson’s disease.Mov Disord. 1997; 12: 952-957
- Gastrointestinal motility problems in patients with Parkinson’s disease. Effects of antiparkinsonian treatment and guidelines for management.Drugs Aging. 1997; 10: 249-258
- Effect of cisapride on response fluctuations in Parkinson’s disease.Mov Disord. 1995; 10: 81-84
- Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson’s disease.Parkinsonism Relat Disord. 2005; 11: 499-502
- Erythromycin: a motilin agonist and gastrointestinal prokinetic agent.Am J Gastroenterol. 1993; 88: 485-490
- Oral erythromycin and symptomatic relief of gastroparesis: a systematic review.Am J Gastroenterol. 2003; 98: 259-263
- Erythromycin in the short- and long-term control of dyspepsia symptoms in patients with gastroparesis.J Clin Gastroenterol. 2004; 38: 237-242
- Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment.Psychosomatics. 2006; 47: 440-442
- Factors associated with symptom response to pyloric injection of botulinum toxin in a large series of gastroparesis patients.Dig Dis Sci. 2009 Jan 30; ([epub ahead of print])
- Botulinum toxin type A for treatment of refractory gastroparesis.Am J Health Syst Pharm. 2007; 64: 2237-2240
- Gastric electrical stimulation for gastroparesis.J Am Coll Surg. 2008; 207: 533-538
- Treatment of gastroparesis: an update.Digestion. 2008; 78: 173-179
- Autonomic dysfunction in Parkinson’s disease: a comprehensive symptom survey.Parkinsonism Relat Disord. 2002; 8: 277-284
- Excess burden of constipation in Parkinson’s disease: a pilot study.Mov Disord. 2006; 21: 1270-1273
- Anorectal function in multiple system atrophy and Parkinson’s disease.Mov Disord. 2000; 15: 71-76
- Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease.Auton Neurosci. 2001; 92: 76-85
- Defecatory disorders in de novo Parkinsonians – colon transit and electromyogram of the external anal sphincter.Wien Klin Wochenschr. 1998; 110: 535-537
- Constipation in Parkinson’s disease: objective assessment and response to psyllium.Mov Disord. 1997; 12: 946-951
- Frequency of bowel movements and the future risk of Parkinson’s disease.Neurology. 2001; 57: 456-462
- Bowel movement frequency in late life and incidental Lewy bodies.Mov Disord. 2007; 22: 1581-1586
- Characterization of swallowing and defecation in Parkinson’s disease.Am J Gastroenterol. 1994; 89: 15-25
- Constipation in Parkinson’s disease.Klin Wochenschr. 1991; 69: 906-909
- The effect of cisapride on delayed colon transit time in patients with idiopathic Parkinson’s disease.Wien Klin Wochenschr. 1994; 106: 673-676
- Colonic transit time and rectoanal videomanometry in Parkinson’s disease.J Neurol Neurosurg Psychiatry. 2003; 74: 268-272
- Measurement of gastrointestinal transit.Dig Dis Sci. 2005; 50: 989-1004
- Management of faecal incontinence and constipation in adults with central neurological diseases.Cochrane Database Syst Rev. 2006; 2: CD002115
- Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study.Mov Disord. 2007; 22: 1239-1244
- Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multiple system atrophy.Mov Disord. 2001; 16: 1176-1177
- Megacolon and volvulus in Parkinson’s disease.Radiology. 1965; 85: 73-79
- Sigmoid volvulus in association with parkinsonism. Report of four cases.J Am Geriatr Soc. 1987; 35: 683-684
- Manometric investigation of anorectal function in early and late stage Parkinson’s disease.J Neurol Neurosurg Psychiatry. 2000; 68: 768-770
- Pathogenesis of slow transit and pelvic floor dysfunction: from bench to bedside.Rev Gastroenterol Disord. 2004; 4: S17-S27
- Anorectal and pelvic floor dysfunction.in: Quigley E.M.M. Pfeiffer R.F. Neuro-gastroenterology. Butterworth Heinemann, Philadelphia2004: 255-271
- Constipation and paradoxical puborectalis contraction in anismus and Parkinson’s disease: a dystonic phenomenon?.J Neurol Neurosurg Psychiatry. 1988; 51: 1503-1507
- Anal sphincter dysfunction in Parkinson’s disease.Arch Neurol. 1989; 46: 1061-1064
- Anorectal manometry in the assessment of anorectal function in Parkinson’s disease: a comparison with chronic idiopathic constipation.Mov Disord. 1994; 9: 655-663
- Anorectal function in fluctuating (on-off) Parkinson’s disease: evaluation by combined anorectal manometry and electromyography.Mov Disord. 1995; 10: 650-657
- Simultaneous electromyography and manometry of the anal sphincters in Parkinsonian patients: technical considerations.Muscle Nerve. 1996; 19: 110-111
- Dyssynergic defecation and biofeedback therapy.Gastroenterol Clin North Am. 2008; 37: 569-586
- The role of biofeedback therapy in functional proctologic disorders.Scand J Surg. 2004; 93: 184-190
- Comparative study between biofeedback retraining and botulinum neurotoxin in the treatment of anismus patients.Int J Colorectal Dis. 2009; 24: 115-120
- Severe constipation in Parkinson’s disease relieved by botulinum toxin.Mov Disord. 1997; 12: 764-766
- Treatment of outlet obstruction constipation in Parkinson’s disease with botulinum neurotoxin A.Am J Gastroenterol. 2003; 98: 1439-1440
- Outlet type constipation in Parkinson’s disease: results of botulinum toxin treatment.Aliment Pharmacol Ther. 2005; 22: 997-1003
- Defecatory function in Parkinson’s disease: response to apomorphine.Ann Neurol. 1993; 33: 490-493
- Overview of morphological changes in Parkinson’s disease.in: Yahr M.D. Bergmann K.J. Parkinson’s disease. Advances in neurology. vol. 45. Raven Press, New York1987: 1-18
- Neuropathology of immunohistochemically identified brainstem neurons in Parkinson’s disease.Ann Neurol. 1990; 27: 373-385
- Where does Parkinson disease pathology begin in the brain?.J Neuropathol Exp Neurol. 2002; 61: 413-426
- Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson’s disease.Gastroenterology. 1884; 87: 848-856
- Parkinson’s disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells.Neurology. 1987; 37: 1253-1255
- Parkinson’s disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses.Acta Neuropathol. 1988; 76: 217-221
- Gastric α-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology.Neurosci Lett. 2006; 396: 67-72
- Dopaminergic defect of enteric nervous system in Parkinson’s disease patients with chronic constipation.Lancet. 1995; 346: 861-864
- Parkinson’s disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system.Acta Neuropathol. 1990; 79: 581-583
Article info
Publication history
Accepted:
August 4,
2010
Received:
July 31,
2010
Footnotes
☆Disclosures (2009–2010): Honoraria for lectures: Boehringer-Ingelheim, Novartis, Teva. Honoraria for consulting: Solvay, Theravance, Genactis, Schlesinger Associates. Research Grants/Contracts: Novartis, Boehringer-Ingelheim, UCB/Schwarz, Santhera, Molecular Biometrics. Royalties (for books edited): CRC Press (Taylor & Francis), Humana Press. Legal Consulting: Spriggs & Hollingsworth, Davis Graham & Stubbs, Tucker Ellis & West.
☆☆This paper was presented at the XVIII WFN World Congress on Parkinson's Disease and Related Disorders Miami December 2009.
☆☆☆The review of this paper was entirely handled by the Co-Editor-in-Chief Prof. Z.K. Wszolek.
Identification
Copyright
© 2010 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.
